Lattice Capital Management, LLC Eli Lilly & CO Transaction History

Lattice Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 24, 2024	SELL	$592.2 - $792.28 $236,880 - $316,912	-400 Reduced 9.26%	3,918 $3.05 Million
Q3 2022 Oct 27, 2022	BUY	$296.48 - $337.87 $3,854 - $4,392	13 Added 0.3%	4,318 $1.4 Million
Q2 2022 Jul 27, 2022	BUY	$278.73 - $327.27 $3,623 - $4,254	13 Added 0.3%	4,305 $1.39 Million
Q1 2022 Apr 22, 2022	BUY	$234.69 - $291.66 $3,520 - $4,374	15 Added 0.35%	4,292 $1.3 Billion
Q4 2021 Jan 19, 2022	BUY	$224.85 - $279.04 $961,683 - $1.19 Million	4,277 New	4,277 $1.18 Million

3,887

763M

6.34M

7.97M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $864B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Lattice Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Lattice Capital Management, LLC with notifications on news.